FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194804099> ?p ?o ?g. }

• W3194804099 endingPage "S284" @default.
• W3194804099 startingPage "S284" @default.
• W3194804099 abstract "Objectives: To examine the survival effect of adjuvant therapy in stage II-III endometrial cancer based on peritoneal cytology results. Methods: The Surveillance, Epidemiology, and End Results Program was retrospectively queried to examine 7,467 women with stage II-III endometrial cancer who underwent hysterectomy with available peritoneal cytology results from 2010-2016. Propensity score inverse probability of treatment weighting was used to assess the survival effect of malignant peritoneal cytology, and Cox proportional hazard regression model was fitted to assess the association between adjuvant therapy and all-cause mortality stratified by peritoneal cytology results. Results: Malignant peritoneal cytology was reported in 1,662 (22.3%) women, and was associated with non-endometrioid histology, higher tumor stage, and nodal metastasis in multivariable analysis (all, P<0.05). In a propensity score-weighted model, malignant peritoneal cytology was associated with increased all-cause mortality compared to negative peritoneal cytology (hazard ratio 1.35, 95% confidence interval 1.23-1.48, P<0.001). Adjuvant therapy types varied based on histology and peritoneal cytology results. In non-endometrioid histology, combination of chemotherapy and whole pelvic radiotherapy (WPRT) was associated with improved overall survival compared to chemotherapy or WPRT alone irrespective of peritoneal cytology results (all, P<0.05). Combination of chemotherapy and WPRT was also associated with improved overall survival in women with endometrioid histology and malignant peritoneal cytology (P=0.026). Women with endometrioid histology and negative peritoneal cytology represented the most common subpopulation (46.5%), and overall survival was similar regardless of which of the three adjuvant therapy modalities was used (P=0.319). Conclusions: Malignant peritoneal cytology is prevalent and prognostic in stage II-III endometrial cancer. This study found that the benefit of adjuvant therapy for women with stage II-III endometrial cancer differed depending on the status of peritoneal cytology. To examine the survival effect of adjuvant therapy in stage II-III endometrial cancer based on peritoneal cytology results. The Surveillance, Epidemiology, and End Results Program was retrospectively queried to examine 7,467 women with stage II-III endometrial cancer who underwent hysterectomy with available peritoneal cytology results from 2010-2016. Propensity score inverse probability of treatment weighting was used to assess the survival effect of malignant peritoneal cytology, and Cox proportional hazard regression model was fitted to assess the association between adjuvant therapy and all-cause mortality stratified by peritoneal cytology results. Malignant peritoneal cytology was reported in 1,662 (22.3%) women, and was associated with non-endometrioid histology, higher tumor stage, and nodal metastasis in multivariable analysis (all, P<0.05). In a propensity score-weighted model, malignant peritoneal cytology was associated with increased all-cause mortality compared to negative peritoneal cytology (hazard ratio 1.35, 95% confidence interval 1.23-1.48, P<0.001). Adjuvant therapy types varied based on histology and peritoneal cytology results. In non-endometrioid histology, combination of chemotherapy and whole pelvic radiotherapy (WPRT) was associated with improved overall survival compared to chemotherapy or WPRT alone irrespective of peritoneal cytology results (all, P<0.05). Combination of chemotherapy and WPRT was also associated with improved overall survival in women with endometrioid histology and malignant peritoneal cytology (P=0.026). Women with endometrioid histology and negative peritoneal cytology represented the most common subpopulation (46.5%), and overall survival was similar regardless of which of the three adjuvant therapy modalities was used (P=0.319). Malignant peritoneal cytology is prevalent and prognostic in stage II-III endometrial cancer. This study found that the benefit of adjuvant therapy for women with stage II-III endometrial cancer differed depending on the status of peritoneal cytology." @default.
• W3194804099 created "2021-08-30" @default.
• W3194804099 creator A5000713007 @default.
• W3194804099 creator A5037820269 @default.
• W3194804099 creator A5057686070 @default.
• W3194804099 creator A5066030067 @default.
• W3194804099 creator A5071731375 @default.
• W3194804099 creator A5075566972 @default.
• W3194804099 creator A5078567055 @default.
• W3194804099 date "2021-08-01" @default.
• W3194804099 modified "2023-10-16" @default.
• W3194804099 title "Survival effect of adjuvant therapy in stage II-III endometrial cancer: interaction to malignant peritoneal cytology" @default.
• W3194804099 doi "https://doi.org/10.1016/s0090-8258(21)01191-4" @default.
• W3194804099 hasPublicationYear "2021" @default.
• W3194804099 type Work @default.
• W3194804099 sameAs 3194804099 @default.
• W3194804099 citedByCount "1" @default.
• W3194804099 countsByYear W31948040992022 @default.
• W3194804099 crossrefType "journal-article" @default.
• W3194804099 hasAuthorship W3194804099A5000713007 @default.
• W3194804099 hasAuthorship W3194804099A5037820269 @default.
• W3194804099 hasAuthorship W3194804099A5057686070 @default.
• W3194804099 hasAuthorship W3194804099A5066030067 @default.
• W3194804099 hasAuthorship W3194804099A5071731375 @default.
• W3194804099 hasAuthorship W3194804099A5075566972 @default.
• W3194804099 hasAuthorship W3194804099A5078567055 @default.
• W3194804099 hasConcept C121608353 @default.
• W3194804099 hasConcept C126322002 @default.
• W3194804099 hasConcept C142724271 @default.
• W3194804099 hasConcept C143998085 @default.
• W3194804099 hasConcept C146357865 @default.
• W3194804099 hasConcept C151730666 @default.
• W3194804099 hasConcept C18823058 @default.
• W3194804099 hasConcept C207103383 @default.
• W3194804099 hasConcept C2776694085 @default.
• W3194804099 hasConcept C2777088508 @default.
• W3194804099 hasConcept C2777982462 @default.
• W3194804099 hasConcept C29456083 @default.
• W3194804099 hasConcept C44249647 @default.
• W3194804099 hasConcept C50382708 @default.
• W3194804099 hasConcept C57742111 @default.
• W3194804099 hasConcept C71924100 @default.
• W3194804099 hasConcept C86803240 @default.
• W3194804099 hasConceptScore W3194804099C121608353 @default.
• W3194804099 hasConceptScore W3194804099C126322002 @default.
• W3194804099 hasConceptScore W3194804099C142724271 @default.
• W3194804099 hasConceptScore W3194804099C143998085 @default.
• W3194804099 hasConceptScore W3194804099C146357865 @default.
• W3194804099 hasConceptScore W3194804099C151730666 @default.
• W3194804099 hasConceptScore W3194804099C18823058 @default.
• W3194804099 hasConceptScore W3194804099C207103383 @default.
• W3194804099 hasConceptScore W3194804099C2776694085 @default.
• W3194804099 hasConceptScore W3194804099C2777088508 @default.
• W3194804099 hasConceptScore W3194804099C2777982462 @default.
• W3194804099 hasConceptScore W3194804099C29456083 @default.
• W3194804099 hasConceptScore W3194804099C44249647 @default.
• W3194804099 hasConceptScore W3194804099C50382708 @default.
• W3194804099 hasConceptScore W3194804099C57742111 @default.
• W3194804099 hasConceptScore W3194804099C71924100 @default.
• W3194804099 hasConceptScore W3194804099C86803240 @default.
• W3194804099 hasLocation W31948040991 @default.
• W3194804099 hasOpenAccess W3194804099 @default.
• W3194804099 hasPrimaryLocation W31948040991 @default.
• W3194804099 hasRelatedWork W167319750 @default.
• W3194804099 hasRelatedWork W1758517966 @default.
• W3194804099 hasRelatedWork W2085269729 @default.
• W3194804099 hasRelatedWork W2117571685 @default.
• W3194804099 hasRelatedWork W2307349321 @default.
• W3194804099 hasRelatedWork W2748373020 @default.
• W3194804099 hasRelatedWork W3037269251 @default.
• W3194804099 hasRelatedWork W3153407610 @default.
• W3194804099 hasRelatedWork W3200592310 @default.
• W3194804099 hasRelatedWork W4283324283 @default.
• W3194804099 hasVolume "162" @default.
• W3194804099 isParatext "false" @default.
• W3194804099 isRetracted "false" @default.
• W3194804099 magId "3194804099" @default.
• W3194804099 workType "article" @default.